OAKLAND and BERKELEY, Calif., Sept. 29, 2015 /PRNewswire/ — EnChroma – the company bringing color to the color blind – and The Clorox Company (NYSE: CLX), today announced a $10,000 gift from Clorox 2 to purchase and distribute EnChroma’s glasses to color blind schoolchildren. EnChroma’s Cx indoor glasses can enable red-green color blind kids to more quickly and accurately interpret color-coded information at school.
To bring to life the impact of seeing certain colors for the first time, Clorox 2 and EnChroma today unveiled a video that captures a family in Indiana with eight brothers – all of whom are color blind – trying on EnChroma glasses. The statistical odds of eight siblings in one family being color blind is one in 255, or half of one percent (0.4%). The eight boys are the first beneficiaries of Clorox’s donation. read more
Ocular Therapeutix™ Submits New Drug Application to U.S. Food and Drug Administration for DEXTENZA® for the Treatment of Post-Surgical Ocular Pain
BEDFORD, Mass.–(EON: Enhanced Online News)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA® (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of ocular pain following ophthalmic surgery. The data included in the NDA submission are from a Phase 2 clinical trial and two Phase 3 clinical trials conducted with this product candidate. read more
Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis
INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response rate after 24 weeks of treatment. Additionally, baricitinib was superior to methotrexate based on ACR20 response. read more
Ferring Pharmaceuticals acquires global rights to MILPROSATM (progesterone vaginal ring
SAINT-PREX, Switzerland–(EON: Enhanced Online News)–Ferring Pharmaceuticals announced today that it has acquired the global rights to MILPROSATM (progesterone vaginal ring) from Teva Women’s Health, Inc. MILPROSA has the potential to be the first once-weekly progesterone treatment for luteal phase support in women undergoing Assisted Reproductive Technology (ART) treatment if approved by regulatory authorities in the United States. read more
Colorectal Cancer: Targeted and Immune System-based Therapeutics Emerge as Prominent Treatment Modalities
LONDON, Sept. 29, 2015 /PRNewswire/ — A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market. To stay competitive, participants are focussing on identifying new targets, enhancing overall survival at the early treatment stage, and reducing toxicity.
New analysis from Frost & Sullivan, Product and Pipeline Analysis of the Global Colorectal Cancer Market (https://www.frost.com/m986), finds that advanced targeted therapies are dominating the colorectal cancer pipeline, accounting for 60 percent of the drugs under development. This trend remains in line with the broader oncology market’s shift away from standard cytotoxic regimens toward tumour-specific, personalised modalities.
For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_M986-52_18Sept15